A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

[1]  T. Barbui,et al.  Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia , 2010, Haematologica.

[2]  O. Abdel-Wahab,et al.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.

[3]  D. Gilliland,et al.  Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. , 2009, Blood.

[4]  S. Fiering,et al.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. , 2009, Blood.

[5]  A. Salar,et al.  Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients , 2009, British journal of haematology.

[6]  T. Barbui,et al.  Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. , 2009, Blood.

[7]  F. Passamonti,et al.  Clinical relevance of JAK2 (V617F) mutant allele burden , 2009, Haematologica.

[8]  A. Gratwohl,et al.  The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders , 2008, Haematologica.

[9]  J. Spivak,et al.  Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. , 2008, Experimental hematology.

[10]  G. Barosi,et al.  Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders , 2008, Leukemia.

[11]  P. Campbell,et al.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment , 2008, Leukemia.

[12]  M. Cazzola,et al.  Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.

[13]  R. Mesa,et al.  Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.

[14]  R. Tiedt,et al.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.

[15]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. , 2007, Blood.

[16]  A. Tefferi,et al.  Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[17]  A. Pardanani.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.

[18]  M. Møller,et al.  The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis – impact on disease phenotype , 2007, European journal of haematology.

[19]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[20]  A. Tefferi,et al.  Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation , 2007, British journal of haematology.

[21]  Paola Guglielmelli,et al.  Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.

[22]  M. Cazzola,et al.  Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. , 2007, Blood.

[23]  T. Barbui,et al.  Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden , 2007, Leukemia.

[24]  T. Barbui,et al.  How I treat patients with polycythemia vera. , 2007, Blood.

[25]  T. Barbui,et al.  Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. , 2007, Blood.

[26]  Soon-Siong Teo,et al.  Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. , 2006, Blood.

[27]  J. Spivak,et al.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. , 2006, Blood.

[28]  P. Campbell,et al.  Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. , 2006, Blood.

[29]  François Girodon,et al.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. , 2006, Blood.

[30]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[31]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[32]  M. Cazzola,et al.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.

[33]  M. Wadleigh,et al.  The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera , 2006, Cancer.

[34]  W. Vainchenker,et al.  Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis , 2006, Leukemia.

[35]  R. Kralovics,et al.  The JAK 2V 617 F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera , 2006 .

[36]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[37]  M. Cazzola,et al.  Leukemic transformation of polycythemia vera , 2005, Cancer.

[38]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[39]  T. Barbui,et al.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Barbui,et al.  Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. , 2005 .

[41]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[42]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.

[43]  T. Barbui,et al.  Efficacy and safety of low-dose aspirin in polycythemia vera. , 2004, The New England journal of medicine.